4.2 Review

Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review

期刊

MODERN RHEUMATOLOGY
卷 28, 期 5, 页码 789-799

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14397595.2017.1416940

关键词

Low disease activity; rheumatoid arthritis; remission; residual symptom; systematic literature review

资金

  1. Tanabe Mitsubishi Pharma
  2. AbbVie
  3. Bristol-Myers K.K.
  4. Eisai
  5. UCB
  6. Pfizer Japan
  7. Takeda Pharmaceutical
  8. Eli Lilly
  9. Astellas Pharma
  10. Chugai Pharmaceutical
  11. Kyowa Hakko Kirin
  12. TaishoToyama
  13. Janssen
  14. EA Pharma
  15. Ayumi Pharmaseutical
  16. Eli Lilly Japan K.K

向作者/读者索取更多资源

Objectives: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA).Methods: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens.Results: Fifty-one publications were identified through an eDatabase search. Together with 17 articles found through other sources, 68 were included for full text review. The most commonly reported residual symptoms were pain (number of studies=25), fatigue (n=21) and morning stiffness (n=5). Reported disease burdens included mental health (n=15), sleep disturbances (n=7) and work productivity (n=5), impairment in quality of life (n=21), and functional disability (n=34). Substantial residual symptoms and disease burdens were found to be present in patients in remission or LDA.Conclusion: This is the first SLR to investigate residual symptoms and disease burdens in RA patients in remission or LDA. The results indicate that despite achieving conventional clinical targets, the disease continues to affect patients, suggesting the existence of unmet need under the current treatment paradigm.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据